Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Debt (2016 - 2023)

Marker Therapeutics (MRKR) has disclosed Total Debt for 7 consecutive years, with $97400.0 as the latest value for Q1 2023.

  • Quarterly Total Debt changed N/A to $97400.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $97400.0 through Mar 2023, changed N/A year-over-year, with the annual reading at $2.5 million for FY2022, N/A changed from the prior year.
  • Total Debt for Q1 2023 was $97400.0 at Marker Therapeutics, down from $2.5 million in the prior quarter.
  • The five-year high for Total Debt was $8.1 million in Q2 2022, with the low at $31000.0 in Q4 2019.
  • Average Total Debt over 3 years is $2.0 million, with a median of $113200.0 recorded in 2019.
  • Peak annual rise in Total Debt hit 625.0% in 2019, while the deepest fall reached 55.78% in 2019.
  • Over 3 years, Total Debt stood at $31000.0 in 2019, then skyrocketed by 7964.52% to $2.5 million in 2022, then crashed by 96.1% to $97400.0 in 2023.
  • According to Business Quant data, Total Debt over the past three periods came in at $97400.0, $2.5 million, and $5.1 million for Q1 2023, Q4 2022, and Q3 2022 respectively.